medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2024-043medsovet-8125Research ArticleЗАБОЛЕВАНИЯ КОЖИDERMAL DISEASESТерапия среднетяжелого бляшечного псориазаTherapy of moderate-to-severe plaque psoriasishttps://orcid.org/0000-0001-5723-6573ЖуковаО. В.ZhukovaO. V.

Жукова Ольга Валентиновна - д.м.н., профессор, заведующая кафедрой дерматовенерологии и аллергологии с курсом иммунологии Медицинского института, РУДН им. Патриса Лумумбы; главный врач, МНПЦДК.

117198, Москва, ул. Миклухо-Маклая, д. 6; 119071, Москва, Ленинский проспект, д. 17

Olga V. Zhukova - Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology and Allergology with the Course of Immunology, Institute of Medicine, Peoples’ Friendship University of Russia named after Patrice Lumumba; Chief Medical Officer, Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology.

6, Miklukho-Maklai St., Moscow, 117198; 17, Leninskiy Ave., Moscow, 119071

klinderma@inbox.ruhttps://orcid.org/0000-0002-2793-8862АртемьеваС. И.ArtemyevaS. I.

Артемьева Софья Иосифовна - научный сотрудник отдела клинической дерматовенерологии и косметологии, врач-дерматовенеролог.

119071, Москва, Ленинский проспект, д. 17

Sofya I. Artemyeva - Researcher and Dermatovenerologist Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology.

17, Leninskiy Ave., Moscow, 119071

sofya.chern@gmail.comРоссийский университет дружбы народов имени Патриса Лумумбы; Московский научно-практический центр дерматовенерологии и косметологииРоссияPeoples’ Friendship University of Russia named after Patrice Lumumba; Moscow Scientific and Practical Center of Dermatovenereology and CosmetologyRussian FederationМосковский научно-практический центр дерматовенерологии и косметологииРоссияMoscow Scientific and Practical Center of Dermatovenereology and CosmetologyRussian Federation202406032024023442Copyright © Жукова О.В., Артемьева С.И., 20242024Жукова О.В., Артемьева С.И.Zhukova O.V., Artemyeva S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/8125

Терапия псориаза является актуальной проблемой в современной медицине. На сегодняшний день достигнут большой прогресс в области генно-инженерной биологической терапии (ГИБТ) псориатической болезни. Новая парадигма лечения стала возможной благодаря постоянному углублению знаний патофизиологии заболевания. ГИБТ представляет собой усовершенствованную схему лечения, в которой целенаправленная иммуномодуляция привела к значительному повышению безопасности и эффективности биологических агентов. Понимание ключевой роли интерлейкина-23 (ИЛ-23) в патогенезе псориаза привело к разработке новых препаратов. Рисанкизумаб – это гуманизированное моноклональное антитело, иммуноглобулин класса G1, специфически нацеленное на ингибирование цитокина ИЛ-23 за счет связывания с его субъединицей p19. Эффективность и безопасность препарата были доказаны как результатами клинических исследований, так и исследований реальной клинической практики. В статье приведены ключевые данные возможности применения препарата рисанкизумаб, а также описан клинический опыт ведения пациента с псориазом и отягощенным коморбидным фоном. В настоящее время известно, что существенной проблемой ведения пациентов, получающих ГИБТ, является наличие коморбидных заболеваний, отмечены сложность достижения оптимального контроля лечения, снижение ответа на терапию и повышение рисков нежелательных явлений. Представленное клиническое наблюдение подтверждает эффективность и безопасность назначения терапии препаратом рисанкизумаб у пациентов с псориазом и сопутствующими заболеваниями. Таким образом, рисанкизумаб представляет собой перспективный препарат для лечения среднетяжелых и тяжелых форм псориаза, его применение может значительно улучшить качество жизни пациентов, страдающих от данного заболевания.

Psoriasis therapy is an acute issue in modern medicine. To date, much progress has been made in the field of genetically engineered biological therapy (GEBT) for psoriatic disease. The new treatment paradigm was made possible by the continuous advancement of understanding of the pathophysiology of the disease. GEBT represents an evolved treatment regimen in which targeted immunomodulation has led to significant improvements in the safety and efficacy of biological agents. Understanding the key role of interleukin-23 (IL) in the pathogenesis of psoriasis has led to the development of new drugs. Risankizumab is a humanised monoclonal antibody – immunoglobulin class G1 – specifically targeted at cytokine IL-23 inhibition by binding to its subunit p19. The efficacy and safety of the agent have been demonstrated both by the results of clinical trials and studies of real clinical practice. The article presents key data on the applicability of the drug risankizumab, and describes the clinical experience of managing a patient with psoriasis and aggravated comorbid conditions. It is currently known that a significant problem in the management of patients receiving GEBT is the presence of comorbid diseases. Difficulty in optimal treatment control, decreased response to therapy and increased risks of adverse events have all been noted. This study confirms the efficacy and safety of risankizumab therapy in patients with psoriasis and comorbidities. Thus, risankizumab is a promising drug for the treatment of moderate and severe forms of psoriasis, its use can significantly improve the quality of life of patients suffering from this disease.

псориазрисанкизумабгенно-инженерная биологическая терапияингибиторы интерлейкина-23качество жизниклинический случайpsoriasisrisankizumabgenetically engineered biologic therapyinterleukin 23 inhibitorsquality of lifeclinical case reportReferencesGisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–99. https://doi.org/10.1016/j.coph.2019.05.007.Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–99. https://doi.org/10.1016/j.coph.2019.05.007.Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. https://doi.org/10.1016/j.jaad.2016.07.064.Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. https://doi.org/10.1016/j.jaad.2016.07.064.Gooderham MJ, Papp KA, Lynde CW. Shifting the focus – the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119. https://doi.org/10.1111/jdv.14868.Gooderham MJ, Papp KA, Lynde CW. Shifting the focus – the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119. https://doi.org/10.1111/jdv.14868.Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. https://doi.org/10.1111/dth.15030.Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. https://doi.org/10.1111/dth.15030.Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022;35(1):e15166. https://doi.org/10.1111/dth.15166.Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022;35(1):e15166. https://doi.org/10.1111/dth.15166.Megna M, Cirillo T, Balato A, Balato N, Gallo L. Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs. J Eur Acad Dermatol Venereol. 2019;33(1):e22–e23. https://doi.org/10.1111/jdv.15119.Megna M, Cirillo T, Balato A, Balato N, Gallo L. Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs. J Eur Acad Dermatol Venereol. 2019;33(1):e22–e23. https://doi.org/10.1111/jdv.15119.Narcisi A, Valenti M, Cortese A, Toso F, Pavia G, Gargiulo L et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. https://doi.org/10.1111/dth.15228.Narcisi A, Valenti M, Cortese A, Toso F, Pavia G, Gargiulo L et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. https://doi.org/10.1111/dth.15228.Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J et al. Comparison of biologics and Oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. https://doi.org/10.1001/jamadermatol.2019.4029.Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J et al. Comparison of biologics and Oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. https://doi.org/10.1001/jamadermatol.2019.4029.Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50(2):e41–e68. https://doi.org/10.1111/1346-8138.16691.Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50(2):e41–e68. https://doi.org/10.1111/1346-8138.16691.Blair HA. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs. 2020;80(12):1235–1245. https://doi.org/10.1007/s40265-020-01357-1.Blair HA. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs. 2020;80(12):1235–1245. https://doi.org/10.1007/s40265-020-01357-1.Warren R, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2020;184(1):50–59. https://doi.org/10.1111/bjd.19341.Warren R, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2020;184(1):50–59. https://doi.org/10.1111/bjd.19341.Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. https://doi.org/10.1016/S0140-6736(19)30952-3.Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. https://doi.org/10.1016/S0140-6736(19)30952-3.Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. https://doi.org/10.1016/S0140-6736(18)31713-6.Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. https://doi.org/10.1016/S0140-6736(18)31713-6.Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830–2838. https://doi.org/10.1111/jdv.16521.Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830–2838. https://doi.org/10.1111/jdv.16521.Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG et al. Long-term safety of Risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475. https://doi.org/10.1111/bjd.20818.Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG et al. Long-term safety of Risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475. https://doi.org/10.1111/bjd.20818.Gordon KB, Blauvelt A, Bachelez H, Coates L, Kaplan B, Koetse W et al. Long-term safety in patients with psoriatic disease: integrated analyses of data from psoriasis and psoriatic arthritis clinical trials. Arthritis Rheumatol. 2023;75(9). Available at: https://acrabstracts.org/abstract/long-term-safety-of-risankizumab-in-patients-with-psoriatic-disease-integrated-analysis-of-psoriasis-and-psoriatic-arthritis-clinical-trial-data/.Gordon KB, Blauvelt A, Bachelez H, Coates L, Kaplan B, Koetse W et al. Long-term safety in patients with psoriatic disease: integrated analyses of data from psoriasis and psoriatic arthritis clinical trials. Arthritis Rheumatol. 2023;75(9). Available at: https://acrabstracts.org/abstract/long-term-safety-of-risankizumab-in-patients-with-psoriatic-disease-integrated-analysis-of-psoriasis-and-psoriatic-arthritis-clinical-trial-data/.Blauvelt A, Papp KA, Gooderham M, Langley RG, Leonardi C, Lacour J-Ph et al. Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance. Acta Derm Venereol. 2018.Blauvelt A, Papp KA, Gooderham M, Langley RG, Leonardi C, Lacour J-Ph et al. Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance. Acta Derm Venereol. 2018.Leonardi C, Leonardi CL, Lebwohl M, Gordon K, Longcore M, Papp KA et al. Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: an analysis of patients from UltIMMa-1 andLeonardi C, Leonardi CL, Lebwohl M, Gordon K, Longcore M, Papp KA et al. Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: an analysis of patients from UltIMMa-1 andMegna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020;33(6):e14144. https://doi.org/10.1111/dth.14144.Megna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020;33(6):e14144. https://doi.org/10.1111/dth.14144.Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study. J Dermatol Treat. 2022;33(6):2813–2820. https://doi.org/10.1080/09546634.2022.2081655.Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study. J Dermatol Treat. 2022;33(6):2813–2820. https://doi.org/10.1080/09546634.2022.2081655.Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: Preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623. https://doi.org/10.1007/s00403-021-02200-7.Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: Preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623. https://doi.org/10.1007/s00403-021-02200-7.Sotiriou E, Bakirtzi K, Papadimitriou I, Tsentemeidou A, Eftychidou P, Eleftheriadis V et al. A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: A real-life, 24-week, prospective study. J Eur Acad Dermatol Venereol. 2021;36(5):e359–e361. https://doi.org/10.1111/jdv.17880.Sotiriou E, Bakirtzi K, Papadimitriou I, Tsentemeidou A, Eftychidou P, Eleftheriadis V et al. A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: A real-life, 24-week, prospective study. J Eur Acad Dermatol Venereol. 2021;36(5):e359–e361. https://doi.org/10.1111/jdv.17880.Borroni RG, Malagoli P, Gargiulo L, Valenti M, Pavia G, Facheris P et al. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study. Acta Derm Venereol. 2021;101(11):adv00605. https://doi.org/10.2340/actadv.v101.283.Borroni RG, Malagoli P, Gargiulo L, Valenti M, Pavia G, Facheris P et al. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study. Acta Derm Venereol. 2021;101(11):adv00605. https://doi.org/10.2340/actadv.v101.283.Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M et al. Long-Term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-Label Extension Trial for up to 5 Years of Follow-Up. J Am Acad Dermatol. 2023;89(6):1149–1158. https://doi.org/10.1016/j.jaad.2023.07.1024.Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M et al. Long-Term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-Label Extension Trial for up to 5 Years of Follow-Up. J Am Acad Dermatol. 2023;89(6):1149–1158. https://doi.org/10.1016/j.jaad.2023.07.1024.Papp K, Lebwohl M, Puig L, Ohtsuki M, Beissert S, Zeng J et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135–1145. https://doi.org/10.1111/bjd.20595.Papp K, Lebwohl M, Puig L, Ohtsuki M, Beissert S, Zeng J et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135–1145. https://doi.org/10.1111/bjd.20595.Gooderham M, Pinter A, Ferris L, Warren R, Zhan T, Zeng J et al. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: A post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):855–865. https://doi.org/10.1111/jdv.18010.Gooderham M, Pinter A, Ferris L, Warren R, Zhan T, Zeng J et al. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: A post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):855–865. https://doi.org/10.1111/jdv.18010.Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. https://doi.org/10.1111/dth.15524.Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. https://doi.org/10.1111/dth.15524.Warren RB. Efficacy and safety of risankizumab in psoriasis patients who had a suboptimal response to secukinumab or ixekizumabl. In: 31st Congress of the European Academy of Dermatology and Venerology. Milan, Italy, 7–10 September, 2022.Warren RB. Efficacy and safety of risankizumab in psoriasis patients who had a suboptimal response to secukinumab or ixekizumabl. In: 31st Congress of the European Academy of Dermatology and Venerology. Milan, Italy, 7–10 September, 2022.Caldarola G, Zangrilli A, Bernardini N, Bavetta M, De Simone C, Graceffa D et al. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489. https://doi.org/10.1111/dth.15489.Caldarola G, Zangrilli A, Bernardini N, Bavetta M, De Simone C, Graceffa D et al. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489. https://doi.org/10.1111/dth.15489.Gargiulo L, Ibba L, Pavia G, Vignoli CA, Piscazzi F, Valenti M et al. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study. Dermatol Ther (Heidelb). 2022;12(10):2309–2324. https://doi.org/10.1007/s13555-022-00795-x.Gargiulo L, Ibba L, Pavia G, Vignoli CA, Piscazzi F, Valenti M et al. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study. Dermatol Ther (Heidelb). 2022;12(10):2309–2324. https://doi.org/10.1007/s13555-022-00795-x.Strober B, Ferris L, Duffin КС, Janak JC, Sima АР, Eckmann Т et al. Real-World Achievement of Absolute Psoriasis Area and Severity Index Thresholds With Persistent 18-Month Risankizumab Use in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024;90:82–90. Available at: https://www.jaad.org/article/S0190-9622(23)02848-7/pdf.Strober B, Ferris L, Duffin КС, Janak JC, Sima АР, Eckmann Т et al. Real-World Achievement of Absolute Psoriasis Area and Severity Index Thresholds With Persistent 18-Month Risankizumab Use in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024;90:82–90. Available at: https://www.jaad.org/article/S0190-9622(23)02848-7/pdf.Megna M, Ocampo-Garza SS, Potestio L, Fontanella G, Gallo L, Cacciapuoti S et al. New-onset psoriatic arthritis under biologics in psoriasis patients: An increasing challenge? Biomedicines. 2021;9(10):1482. https://doi.org/10.3390/biomedicines9101482.Megna M, Ocampo-Garza SS, Potestio L, Fontanella G, Gallo L, Cacciapuoti S et al. New-onset psoriatic arthritis under biologics in psoriasis patients: An increasing challenge? Biomedicines. 2021;9(10):1482. https://doi.org/10.3390/biomedicines9101482.Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, Patruno C. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181(3):604–606. https://doi.org/10.1111/bjd.17779.Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, Patruno C. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181(3):604–606. https://doi.org/10.1111/bjd.17779.Megna M, Ocampo-Garza SS, Fabbrocini G, Potestio L. Letter to the editor submitted in response to “Should the presence of psoriatic arthritis change how we manage psoriasis?”. J Dermatol Treatment. 2022;33(5):2695–2696. https://doi.org/10.1080/09546634.2022.2037495.Megna M, Ocampo-Garza SS, Fabbrocini G, Potestio L. Letter to the editor submitted in response to “Should the presence of psoriatic arthritis change how we manage psoriasis?”. J Dermatol Treatment. 2022;33(5):2695–2696. https://doi.org/10.1080/09546634.2022.2037495.Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018;37(7):1739–1741.Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018;37(7):1739–1741.

The authors declare that there are no conflicts of interest present.